Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GenSci155 in Healthy Adults
NCT07638800Phase 1Not yet recruiting
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Jul 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in insulin-like growth factor 1 deficiency comparing GenSci155 Injection with Placebo (2 arms). Primary endpoint: Treatment-Emergent Adverse Events at 31 days. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
GenSci155
03
Conditions
insulin-like growth factor 1 deficiency
Beyond the preview
Go deeper on NCT07638800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07638800.